2 Deaths In China Reopen Gene Therapy Debates

Two undisclosed deaths in China have reopened questions about transparency and oversight in gene therapy. The deaths occurred under China's investigator-initiated trial pathway, which allows hospitals to run experimental medicines without direct oversight from the National Medical Products Administration. The source states that the two most recent gene-editing deaths in China matter because they have reignited debate about safeguards and disclosure in the field.